ICD-10-CM Code C90.3

Solitary plasmacytoma

Version 2021 Non-Billable Code

Not Valid for Submission

C90.3 is a "header" nonspecific and non-billable code code, consider using a code with a higher level of specificity for a diagnosis of solitary plasmacytoma. The code is NOT valid for the year 2021 for the submission of HIPAA-covered transactions.

ICD-10:C90.3
Short Description:Solitary plasmacytoma
Long Description:Solitary plasmacytoma

Consider the following ICD-10 codes with a higher level of specificity:

  • C90.30 - Solitary plasmacytoma not having achieved remission
  • C90.31 - Solitary plasmacytoma in remission
  • C90.32 - Solitary plasmacytoma in relapse

Tabular List of Diseases and Injuries

The Tabular List of Diseases and Injuries is a list of ICD-10 codes, organized "head to toe" into chapters and sections with guidance for inclusions, exclusions, descriptions and more. The following references are applicable to the code C90.3:

Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Localized malignant plasma cell tumor NOS
  • Plasmacytoma NOS
  • Solitary myeloma

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C90.3 are found in the index:


Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
      • Multiple myeloma and malignant plasma cell neoplasms (C90)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021

Information for Patients


Multiple Myeloma

Also called: Plasma-cell myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.

No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include

  • Bone pain, often in the back or ribs
  • Broken bones
  • Weakness or fatigue
  • Weight loss
  • Frequent infections and fevers
  • Feeling very thirsty
  • Frequent urination

Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute

  • Bence-Jones protein - quantitative (Medical Encyclopedia)
  • Bone marrow transplant (Medical Encyclopedia)
  • Multiple myeloma (Medical Encyclopedia)
  • Protein electrophoresis - serum (Medical Encyclopedia)
  • Serum globulin electrophoresis (Medical Encyclopedia)

[Learn More]